Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
07 06 2021
Historique:
received: 10 11 2020
accepted: 11 05 2021
entrez: 8 6 2021
pubmed: 9 6 2021
medline: 23 6 2021
Statut: epublish

Résumé

Characterizing the human leukocyte antigen (HLA) bound ligandome by mass spectrometry (MS) holds great promise for developing vaccines and drugs for immune-oncology. Still, the identification of non-tryptic peptides presents substantial computational challenges. To address these, we synthesized and analyzed >300,000 peptides by multi-modal LC-MS/MS within the ProteomeTools project representing HLA class I & II ligands and products of the proteases AspN and LysN. The resulting data enabled training of a single model using the deep learning framework Prosit, allowing the accurate prediction of fragment ion spectra for tryptic and non-tryptic peptides. Applying Prosit demonstrates that the identification of HLA peptides can be improved up to 7-fold, that 87% of the proposed proteasomally spliced HLA peptides may be incorrect and that dozens of additional immunogenic neo-epitopes can be identified from patient tumors in published data. Together, the provided peptides, spectra and computational tools substantially expand the analytical depth of immunopeptidomics workflows.

Identifiants

pubmed: 34099720
doi: 10.1038/s41467-021-23713-9
pii: 10.1038/s41467-021-23713-9
pmc: PMC8184761
doi:

Substances chimiques

ASPN protein, human 0
Epitopes 0
Extracellular Matrix Proteins 0
HLA Antigens 0
Histocompatibility Antigens Class I 0
Histocompatibility Antigens Class II 0
Ligands 0
Peptides 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3346

Subventions

Organisme : NCI NIH HHS
ID : U01 CA214125
Pays : United States
Organisme : NCI NIH HHS
ID : U24 CA210986
Pays : United States

Commentaires et corrections

Type : ErratumIn

Références

Nat Methods. 2017 May;14(5):513-520
pubmed: 28394336
Proteomics. 2020 Nov;20(21-22):e1900345
pubmed: 32574431
Blood. 2011 Aug 25;118(8):2128-37
pubmed: 21715316
Nature. 2017 Jul 13;547(7662):222-226
pubmed: 28678784
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Mol Cell Proteomics. 2011 Oct;10(10):O111.011833
pubmed: 21813418
Sci Immunol. 2019 Aug 16;4(38):
pubmed: 31420320
Cancer Immunol Res. 2019 Jan;7(1):62-76
pubmed: 30425108
Sci Data. 2020 May 15;7(1):146
pubmed: 32415162
J Am Soc Mass Spectrom. 2016 Nov;27(11):1719-1727
pubmed: 27572102
Science. 2016 Oct 21;354(6310):354-358
pubmed: 27846572
Nucleic Acids Res. 2018 Jan 4;46(D1):D1237-D1247
pubmed: 28985418
Mol Syst Biol. 2019 Feb 18;15(2):e8503
pubmed: 30777892
Nat Biotechnol. 2013 Mar;31(3):213-9
pubmed: 23396013
Nature. 2017 Jul 13;547(7662):217-221
pubmed: 28678778
Bioinformatics. 2017 Nov 15;33(22):3645-3647
pubmed: 29036507
Biopolymers. 2000;55(3):188-206
pubmed: 11074414
Proteomics. 2020 Nov;20(21-22):e1900334
pubmed: 32864883
Nat Methods. 2017 Mar;14(3):259-262
pubmed: 28135259
Bioinformatics. 2016 Feb 15;32(4):511-7
pubmed: 26515819
Proteomics. 2017 Nov;17(21):
pubmed: 28872757
Science. 1992 Mar 6;255(5049):1261-3
pubmed: 1546328
Immunity. 2017 Feb 21;46(2):315-326
pubmed: 28228285
Mol Cell Proteomics. 2018 Dec;17(12):2347-2357
pubmed: 30171158
Nat Biotechnol. 2020 Feb;38(2):199-209
pubmed: 31844290
Bioinformatics. 2019 Dec 15;35(24):5243-5248
pubmed: 31077310
J Proteome Res. 2017 Mar 3;16(3):1288-1299
pubmed: 28164708
Mol Cell Proteomics. 2015 Mar;14(3):658-73
pubmed: 25576301
Nat Protoc. 2016 Dec;11(12):2301-2319
pubmed: 27809316
Nucleic Acids Res. 2019 Jan 8;47(D1):D339-D343
pubmed: 30357391
Nat Methods. 2019 Jun;16(6):509-518
pubmed: 31133760
Nat Methods. 2018 Aug;15(8):591-594
pubmed: 30013048
Sci Immunol. 2018 Oct 12;3(28):
pubmed: 30315122
Nat Methods. 2013 Oct;10(10):989-91
pubmed: 23975139
Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4507-12
pubmed: 24616531
Nat Commun. 2016 Nov 21;7:13404
pubmed: 27869121
J Proteome Res. 2020 Mar 6;19(3):1267-1274
pubmed: 32009418

Auteurs

Mathias Wilhelm (M)

Computational Mass Spectrometry, Technical University of Munich (TUM), Freising, Germany. mathias.wilhelm@tum.de.
Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany. mathias.wilhelm@tum.de.

Daniel P Zolg (DP)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

Michael Graber (M)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

Siegfried Gessulat (S)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

Tobias Schmidt (T)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

Karsten Schnatbaum (K)

JPT Peptide Technologies GmbH, Berlin, Germany.

Celina Schwencke-Westphal (C)

Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Philipp Seifert (P)

Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Niklas de Andrade Krätzig (N)

Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.
Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.
Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Johannes Zerweck (J)

JPT Peptide Technologies GmbH, Berlin, Germany.

Tobias Knaute (T)

JPT Peptide Technologies GmbH, Berlin, Germany.

Eva Bräunlein (E)

Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Patroklos Samaras (P)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

Ludwig Lautenbacher (L)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany.

Susan Klaeger (S)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Holger Wenschuh (H)

JPT Peptide Technologies GmbH, Berlin, Germany.

Roland Rad (R)

Center for Translational Cancer Research (TranslaTUM), TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.
Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.
Klinik und Poliklinik für Innere Medizin II, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Bernard Delanghe (B)

Thermo Fisher Scientific, Bremen, Germany.

Andreas Huhmer (A)

Thermo Fisher Scientific, San Jose, CA, USA.

Steven A Carr (SA)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Karl R Clauser (KR)

Broad Institute of MIT and Harvard, Cambridge, MA, USA.

Angela M Krackhardt (AM)

Klinik und Poliklinik für Innere Medizin III, Klinikum rechts der Isar, School of Medicine, Technical University of Munich (TUM), Munich, Germany.
German Cancer Consortium (DKTK), partner site Munich; and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Institute of Molecular Oncology and Functional Genomics, TUM School of Medicine, Technical University of Munich (TUM), Munich, Germany.

Ulf Reimer (U)

JPT Peptide Technologies GmbH, Berlin, Germany.

Bernhard Kuster (B)

Chair of Proteomics and Bioanalytics, Technical University of Munich (TUM), Freising, Germany. kuster@tum.de.
Bavarian Biomolecular Mass Spectrometry Center (BayBioMS), Technical University of Munich (TUM), Freising, Germany. kuster@tum.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH